发布求助
文献互助 智能选刊 最新文献

Veterinary Therapeutics最新文献

筛选
英文 中文
Hemodynamic effects of an intravenous infusion of medetomidine at six different dose regimens in isoflurane-anesthetized dogs. 六种不同剂量方案静脉输注美托咪定对异氟醚麻醉犬血液动力学的影响。
Veterinary Therapeutics Pub Date : 2010-01-01
Johanna Kaartinen, Daniel Pang, Maxim Moreau, Outi Vainio, Francis Beaudry, Jerome del Castillo, Leigh Lamont, Sophie Cuvelliez, Eric Troncy
{"title":"Hemodynamic effects of an intravenous infusion of medetomidine at six different dose regimens in isoflurane-anesthetized dogs.","authors":"Johanna Kaartinen,&nbsp;Daniel Pang,&nbsp;Maxim Moreau,&nbsp;Outi Vainio,&nbsp;Francis Beaudry,&nbsp;Jerome del Castillo,&nbsp;Leigh Lamont,&nbsp;Sophie Cuvelliez,&nbsp;Eric Troncy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study investigated the dose dependency of the hemodynamic effects of IV medetomidine (MED) constant-rate infusion (CRI) during isoflurane anesthesia. Twenty-four healthy beagles randomly received one of six MED CRI regimens. A loading dose of MED was administered IV at 0.2, 0.5, 1.0, 1.7, 4.0, or 12.0 ug/kg-1 for 10 minutes, followed by a maintenance CRI providing identical dose amounts over 60 minutes. Heart rate and mean arterial blood pressure were recorded, blood gases were analyzed, and cardiac index (CI) was determined. Statistical analysis involved a repeated measures linear model. Baseline CI demonstrated a dose-dependent decrease as the MED dose increased, with decreases of 14.9% (SD, 12.7%), 21.7% (17.9%), 27.1% (13.2%), 44.2% (9.7%), 47.9% (8.1%), and 61.2% (14.1%) at doses of 0.2, 0.5, 1.0, 1.7, 4.0, and 12.0 ug/kg-1, respectively. The four lowest doses induced limited and transient changes in heart rate, mean arterial pressure, and CI. Further investigation into potential perioperative uses of MED CRI is warranted.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 1","pages":"E1-16"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29354252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of buprenorphine in a sodium carboxymethylcellulose gel after buccal transmucosal administration in dogs. 丁丙诺啡在羧甲基纤维素钠凝胶中经口腔黏膜给药后的药代动力学。
Veterinary Therapeutics Pub Date : 2010-01-01
Ursula Krotscheck, Dawn Merton Boothe, Amy A Little, Hollis N Erb
{"title":"Pharmacokinetics of buprenorphine in a sodium carboxymethylcellulose gel after buccal transmucosal administration in dogs.","authors":"Ursula Krotscheck,&nbsp;Dawn Merton Boothe,&nbsp;Amy A Little,&nbsp;Hollis N Erb","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Alternatives to intravenous administration of opioids are needed in veterinary medicine. Previous research suggests that opioids can be administered through the buccal mucosa in dogs. This study reports the pharmacokinetics of buprenorphine HCl (0.05 mg/kg) administered transmucosally in six dogs compared with those of buprenorphine HCl (0.015 mg/kg) administered intravenously. The results suggest that the pharmacokinetics of buprenorphine HCl administered intravenously or transmucosally are similar and that transmucosal administration may be considered as a noninvasive alternative to intravenous administration.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 3","pages":"E1-8"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29367271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of topical 0.5% levobunolol alone or in association with 2% dorzolamide compared with a fixed combination of 0.5% timolol and 2% dorzolamide on intraocular pressure and heart rate in dogs without glaucoma. 与0.5%噻莫洛尔和2%多唑胺固定联合用药相比，局部使用0.5%左旋布洛尔或联合2%多唑胺对无青光眼犬眼压和心率的影响。
Veterinary Therapeutics Pub Date : 2010-01-01
Alessio Scardillo, Michela Pugliese, Massimo De Majo, Pietro P Niutta, Antonio Pugliese
{"title":"Effects of topical 0.5% levobunolol alone or in association with 2% dorzolamide compared with a fixed combination of 0.5% timolol and 2% dorzolamide on intraocular pressure and heart rate in dogs without glaucoma.","authors":"Alessio Scardillo,&nbsp;Michela Pugliese,&nbsp;Massimo De Majo,&nbsp;Pietro P Niutta,&nbsp;Antonio Pugliese","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The goal of glaucoma management is to reduce intraocular pressure (IOP) and maintain it at a level compatible with the health of the optic nerve. New therapies are constantly being sought. Topical instillation of levobunolol 0.5%, alone or with dorzolamide 2%, has a hypotensive effect on the IOP in healthy dogs, and levobunolol combined with dorzolamide produces a stronger hypotensive effect than the combination of timolol and dorzolamide. All animals tolerate these topical medications well with no signs of discomfort, and no ocular side effects have been observed. Levobunolol, alone or in combination with dorzolamide, induces bradycardia, as does timolol with dorzolamide.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 3","pages":"E1-6"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29367277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A noninferiority clinical trial comparing fluconazole and ketoconazole in combination with cephalexin for the treatment of dogs with Malassezia dermatitis. 氟康唑与酮康唑联合头孢氨苄治疗马拉色菌性皮炎的非劣效性临床研究。
Veterinary Therapeutics Pub Date : 2010-01-01
L Sickafoose, G Hosgood, T Snook, R Westermeyer, S Merchant
{"title":"A noninferiority clinical trial comparing fluconazole and ketoconazole in combination with cephalexin for the treatment of dogs with Malassezia dermatitis.","authors":"L Sickafoose,&nbsp;G Hosgood,&nbsp;T Snook,&nbsp;R Westermeyer,&nbsp;S Merchant","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This double-blinded noninferiority clinical trial evaluated the use of oral fluconazole for the treatment of Malassezia dermatitis in dogs by comparing it with use of an accepted therapeutic agent, ketoconazole. Dogs presenting with Malassezia dermatitis were treated with either fluconazole or ketoconazole in addition to cephalexin for concurrent bacterial dermatitis. Statistically significant improvements in cytologic yeast count, clinical signs associated with Malassezia dermatitis, and pruritus were seen with both antifungal treatments. There was no statistical difference between the treatments with regard to the magnitude of reduction in these parameters. These results suggest that fluconazole is at least as effective as ketoconazole for the treatment of dogs with Malassezia dermatitis.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 2","pages":"E1-13"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29363902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Hepatozoon americanum infection: review of the literature and experimental evaluation of efficacy. 治疗美洲肝虫感染:文献回顾及疗效的实验评价。
Veterinary Therapeutics Pub Date : 2010-01-01
Kelly E Allen, Susan E Little, Eileen M Johnson, Joe Hostetler, Roger J Panciera, Sidney A Ewing
{"title":"Treatment of Hepatozoon americanum infection: review of the literature and experimental evaluation of efficacy.","authors":"Kelly E Allen,&nbsp;Susan E Little,&nbsp;Eileen M Johnson,&nbsp;Joe Hostetler,&nbsp;Roger J Panciera,&nbsp;Sidney A Ewing","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>There is no labeled treatment for dogs with American canine hepatozoonosis (ACH), but the drug therapies discussed in this article, although not rapidly curative, may be successful in alleviating acute clinical signs, prolonging life, reducing the number of clinical relapses, and enhancing quality of life. This article also describes a pilot trial conducted to assess the efficacy of a novel treatment approach with ponazuril as a stand-alone parasiticide administered for 4 weeks without follow-up decoquinate treatment. Although extended ponazuril treatment in combination with NSAID administration did ameliorate acute clinical signs associated with ACH, the parasite was not completely cleared with this treatment protocol alone. Long-term decoquinate therapy remains a critical component of successful treatment of ACH.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 4","pages":"E1-8"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29661329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro comparison of Staphylococcus pseudintermedius susceptibility to common cephalosporins used in dogs. 犬常用头孢菌素对假中葡萄球菌的体外敏感性比较。
Veterinary Therapeutics Pub Date : 2010-01-01
Rebekah R Westermeyer, Alma F Roy, Maria S Mitchell, Sandra R Merchant
{"title":"In vitro comparison of Staphylococcus pseudintermedius susceptibility to common cephalosporins used in dogs.","authors":"Rebekah R Westermeyer,&nbsp;Alma F Roy,&nbsp;Maria S Mitchell,&nbsp;Sandra R Merchant","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The in vitro activity of 10 cephalosporin antimicrobial agents against 75 isolates of methicillin-susceptible Staphylococcus pseudintermedius derived from dogs was assessed. The lowest minimal inhibitory concentration for 90% of strains (MIC90) values obtained were for cephalothin, cefovecin, and cefazolin (0.12 ug/mL), followed by ceftiofur and cefoxitin (0.25 ug/mL), cefpodoxime (0.5 ug/mL), and cefaclor and cefadroxil (1 ug/mL). The highest MIC90 values were found for cephalexin and cefixime (2 ug/mL). In this in vitro study, sensitivity to cephalothin was indicative of cephalexin susceptibility, although there were marked differences in MICs. Cephalothin susceptibility was not indicative of susceptibility to all tested cephalosporins, nor was there a clear trend in susceptibility based on cephalosporin generation.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 3","pages":"E1-9"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29367273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seroprevalence of Borrelia burgdorferi-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic. 在罗德岛小动物诊所接种非佐剂重组外表面蛋白a疫苗前后犬中伯氏疏螺旋体特异性C6抗体的血清阳性率
Veterinary Therapeutics Pub Date : 2010-01-01
Daniel Hebert, Andrew Eschner
{"title":"Seroprevalence of Borrelia burgdorferi-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic.","authors":"Daniel Hebert,&nbsp;Andrew Eschner","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A Borrelia burgdorferi antibody screening and vaccination program was established at a 2.5-doctor small animal hospital where no prior program had existed. A commercially available nonadjuvanted recombinant outer surface protein A vaccine was given at day 0, 3 weeks, and 6 months and then yearly based on recommendations by Topfer and Straubinger. Analysis of Lyme-specific serologic results in the hospital's canine patient population over a 33-month period showed that >99% of C6 Lyme antibody-positive dogs had not been immunized, were previously C6 antibody positive, or had not completed the hospital's recommended vaccine protocol. Additionally, the overall seroprevalence of B. burgdorferi C6 antibody decreased in the patient population during the postvaccination period.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 3","pages":"E1-9"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29367274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin distribution of imidacloprid by microautoradiography after topical administration to beagle dogs. 吡虫啉局部给药后小猎犬皮肤显微放射自显影。
Veterinary Therapeutics Pub Date : 2010-01-01
Harish Chopade, David Eigenberg, Eric Solon, Paul Strzemienski, Joe Hostetler, Terry McNamara
{"title":"Skin distribution of imidacloprid by microautoradiography after topical administration to beagle dogs.","authors":"Harish Chopade,&nbsp;David Eigenberg,&nbsp;Eric Solon,&nbsp;Paul Strzemienski,&nbsp;Joe Hostetler,&nbsp;Terry McNamara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To investigate the cutaneous distribution, localization, and persistence of imidacloprid in dogs, Advantage Topical Solution labeled with carbon 14 ((14)C) was topically applied as a single treatment at label rates and application pattern based on body weight to two adult beagles. One dog (8.5 kg) received 1.0 mL of the test solution at a single spot in the interscapular area (14 mg active ingredient/kg body weight); the second dog (12.3 kg) was treated with 2.5 mL of the test solution at four sites, each site receiving approximately 0.625 mL, along the dorsal thoracic and lumbar spine area (21 mg active ingredient/kg body weight). Samples of hair, skin surface residue, and skin taken from the application sites and/or distal body regions of the dogs at four intervals between 7 and 56 days after treatment demonstrated the migration of (14)C radioactivity from the application sites to distal areas of the canine haircoat and skin. The (14)C radioactivity concentrations in the skin biopsy and stratum corneum samples diminished steadily over 56 days after treatment. Microautoradiography of the skin showed focal concentrations of radioactivity in the superficial epidermis, hair follicles, and sebaceous glands. The presence of imidacloprid-derived radioactivity within hair follicles and sebaceous glands and on the skin surface is in good agreement with the reported efficacy of imidacloprid against fleas on dogs and cats for up to 1 month despite posttreatment bathing, shampooing, and/or swimming.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 4","pages":"E1-10"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29661328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ex vivo viability of canine and feline sarcomas: a pilot study. 犬和猫肉瘤的体外生存能力:一项初步研究。
Veterinary Therapeutics Pub Date : 2010-01-01
Nicki Green, Dawn Merton Boothe, Annette Smith, Ralph Henderson, Elizabeth Whitley
{"title":"Ex vivo viability of canine and feline sarcomas: a pilot study.","authors":"Nicki Green,&nbsp;Dawn Merton Boothe,&nbsp;Annette Smith,&nbsp;Ralph Henderson,&nbsp;Elizabeth Whitley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Assay-based chemotherapeutic protocols are common in human gynecologic oncology, most notably for patients with ovarian or breast cancer. The current study examines ex vivo incubation conditions necessary for the assessment of sarcomatous tumor response to potential chemotherapeutic drugs. Slices of sarcomatous tumors were incubated in one of two culture media. Viability indices were measured and compared across time and between media. Neither medium was sufficient to support the growth of sarcomatous tumor tissue slices based on the indices studied. It is likely that sarcomatous tumors require a different approach for ex vivo assessment than their epithelial counterparts. Our long-term goal is to incubate tumor slices with chemotherapeutic agents to predict the in vivo tumor response based on the maintenance or loss of slice viability within this system.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 2","pages":"E1-11"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29363900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares. 甲磺酸培高利特单剂量口服在健康成年母马体内的药代动力学。
Veterinary Therapeutics Pub Date : 2010-01-01
Ronette Gehring, Laurie Beard, Abra Wright, Johann Coetzee, James Havel, Michael Apley
{"title":"Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.","authors":"Ronette Gehring,&nbsp;Laurie Beard,&nbsp;Abra Wright,&nbsp;Johann Coetzee,&nbsp;James Havel,&nbsp;Michael Apley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pituitary pars intermedia dysfunction (PPID) is probably the most common disease of geriatric horses. Affected horses show a variety of clinical signs, including hirsutism, polyuria/polydipsia, immunosuppression, muscle wasting, and laminitis. The most common treatment for PPID is pergolide, a dopamine agonist; however, there are no pharmacokinetic data about the use of this drug in horses. This article describes a study designed to address this complete lack of pharmacokinetic information. The pharmacokinetics of pergolide are described in a small group of relatively young, healthy mares (n = 6), with the objective of generating data on which to base larger studies in the future. To make definitive dosing recommendations to clinicians, more studies will be needed to investigate the relationship between plasma pergolide concentrations and clinical outcomes, as well as the effect of gender, age, and concomitant disease on the absorption and disposition of this drug.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"11 1","pages":"E1-8"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29354254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信